Form 4: Prime Medicine Reprices Director Stock Options

Prime Medicine, Inc. has repriced certain outstanding stock options for Director Wendy Chung to $4.04 per share, aligning with the current market price.

Summary

• Prime Medicine, Inc. (PRME) repriced outstanding stock options for Director Wendy Chung.
• The new exercise price for these options is $4.04 per share, which matched the closing price of PRME common stock on The Nasdaq Global Market on August 1, 2025.
• Options originally granted with exercise prices of $10.54, $17.00, $14.83, and $7.68 were affected by this repricing.
• A total of 106,578 stock options held by the reporting person were repriced.
• The repricing was approved by the Issuer's stockholders under the 2019 Stock Option and Grant Plan and/or the 2022 Stock Option and Incentive Plan.
• All other terms and conditions of the repriced options, including vesting schedules and expiration dates, remain unchanged.

Sentiment

Score: 4

Explanation: The repricing of stock options, while aimed at re-incentivizing key personnel, signals significant past stock price underperformance. This action can be viewed negatively by existing shareholders as it effectively grants insiders a 'do-over' at a lower price, potentially diluting future value.

Positives

• Re-incentivizes Director Wendy Chung by making her stock options 'in-the-money' again, potentially aligning her interests more closely with future stock price appreciation.
• Stockholder approval for the repricing indicates that a formal governance process was followed for this action.

Negatives

• The repricing indicates that the company's stock price has significantly declined, making previously granted options underwater.
• Repricing can be viewed negatively by existing shareholders as it effectively grants insiders a 'do-over' at a lower price, potentially diluting future shareholder value if more options are exercised.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the effective date of the repricing and the expiration dates of the options.

Management Comments

• Management, through the filing, indicated that the stock option repricing was approved by the Issuer's stockholders and set the new exercise price at $4.04, aligning with the closing market price on the repricing date.

Industry Context

Stock option repricing typically occurs in industries where stock prices have experienced significant declines, leading to 'underwater' options. This practice is common in volatile sectors like biotechnology or emerging technology, where companies rely heavily on equity compensation to attract and retain talent. It aims to re-incentivize key personnel by restoring the value of their equity awards, but can be viewed critically by shareholders.

Comparison to Industry Standards

• Stock option repricing is a controversial practice. While it can be necessary for talent retention in a declining market, it deviates from the principle of long-term incentive alignment where options are granted at market price and only gain value with stock appreciation.
• Companies like Zynga (2012) and Groupon (2012) faced shareholder backlash for similar repricings, highlighting the potential for negative investor sentiment.
• In contrast, many mature companies avoid repricing due to governance concerns, preferring new grants or other forms of compensation.
• The repricing by Prime Medicine, Inc. suggests a need to re-motivate its director, potentially due to significant stock price underperformance relative to its initial grant prices, which were as high as $17.00.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative impact due to perceived dilution and the signal of past stock price underperformance.
• Employees/Directors (Option Holders): Positive impact as their options are re-incentivized, potentially improving morale and retention.

Next Steps

• The filing does not specify any future actions or milestones beyond the ongoing vesting schedules of the repriced options.

Key Dates

Recommendation

The stock option repricing indicates significant past stock price underperformance, which is a negative signal. However, the re-incentivization of a director through lower exercise prices could improve long-term alignment and retention. Investors should hold to observe if this re-alignment translates into improved company performance and stock price recovery, while also considering the potential for future dilution.

Keywords

Prime Medicine, PRME, Stock Option Repricing, SEC Form 4, Insider Transaction, Director Compensation, Equity Compensation, Corporate Governance